Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | CASR | P41180 | 5/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 2/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HTR4 | Q13639 | 4/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20116951 | 0.86 | CMKLR1 (0.35) | CASRCMKLR1NLRP3SSTR5POLB | |
| SCHEMBL20116946 | 0.85 | MPO (0.37) | MPONLRP3SSTR5SYKMAPK8 | |
| SCHEMBL22156297 | 0.73 | GRM4 (0.43) | CASRCMKLR1MAPK8MAPK9 | |
| SCHEMBL26137621 | 0.73 | KIF11 (0.34) | CASRCMKLR1NLRP3L3MBTL1POLB | |
| SCHEMBL27701252 | 0.70 | NLRP3 (0.39) | CMKLR1NLRP3SSTR5POLB | |
| SCHEMBL20117051 | 0.70 | SYK (0.36) | NLRP3SSTR5SYKPOLB | |
| SCHEMBL23248568 | 0.69 | SYK (0.36) | BRD4SYK | |
| SCHEMBL22357745 | 0.69 | CASR (0.34) | CASRCMKLR1 | |
| SCHEMBL28018803 | 0.69 | KDM4E (0.41) | NLRP3SSTR5POLB | |
| SCHEMBL20117058 | 0.68 | HTR2A (0.37) | NLRP3SSTR5MAPK8POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | MPO 212/4885CASR 3724/4885BRD4 1356/4885 |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | MPO 212/4885CASR 3724/4885BRD4 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.